Evidence map›Paper›PMID 41279160›Full record

ArticlebioRxiv : the preprint server for biology2025

Discovery of AVI-6451, a Potent and Selective Inhibitor of the SARS-CoV-2 ADP-Ribosylhydrolase Mac1 with Oral Efficacy in vivo.

Priyadarshini Jaishankar, Galen J Correy, Yusuke Matsui, Takaya Togo, Moira M Rachman, Maisie G V Stevens, Eric R Hantz, Jeffrey Zheng, Morgan E Diolaiti, Mauricio Montano and 9 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

19 authors.

Priyadarshini JaishankarDepartment of Pharmaceutical Chemistry, University of California, San Francisco, 600 16 Street, San Francisco, CA 94158, United States.
Galen J CorreyDepartment of Bioengineering and Therapeutic Sciences, University of California, San Francisco, 600 16 Street, San Francisco, CA 94158, United States.
Yusuke MatsuiGladstone Institute of Virology, Gladstone Institutes, 1650 Owens Street, San Francisco, CA 94158.
Takaya TogoDepartment of Pharmaceutical Chemistry, University of California, San Francisco, 600 16 Street, San Francisco, CA 94158, United States.
Moira M RachmanDepartment of Pharmaceutical Chemistry, University of California, San Francisco, 600 16 Street, San Francisco, CA 94158, United States.
Maisie G V StevensHelen Diller Family Comprehensive Cancer Center, University of California, San Francisco, 1450 Third St., San Francisco, CA 94158, United States.
Eric R HantzDepartment of Pharmaceutical Chemistry, University of California, San Francisco, 600 16 Street, San Francisco, CA 94158, United States.
Jeffrey ZhengDepartment of Pharmaceutical Chemistry, University of California, San Francisco, 600 16 Street, San Francisco, CA 94158, United States.
Morgan E DiolaitiHelen Diller Family Comprehensive Cancer Center, University of California, San Francisco, 1450 Third St., San Francisco, CA 94158, United States.
Mauricio MontanoGladstone Institute of Virology, Gladstone Institutes, 1650 Owens Street, San Francisco, CA 94158.
Taha Y TahaGladstone Institute of Virology, Gladstone Institutes, 1650 Owens Street, San Francisco, CA 94158.
Julia RosecransGladstone Institute of Virology, Gladstone Institutes, 1650 Owens Street, San Francisco, CA 94158.
Julius PampelDepartment of Bioengineering and Therapeutic Sciences, University of California, San Francisco, 600 16 Street, San Francisco, CA 94158, United States.
Nevan J KroganDepartment of Bioengineering and Therapeutic Sciences, University of California, San Francisco, 600 16 Street, San Francisco, CA 94158, United States.
Brian K ShoichetDepartment of Pharmaceutical Chemistry, University of California, San Francisco, 600 16 Street, San Francisco, CA 94158, United States.
Alan AshworthHelen Diller Family Comprehensive Cancer Center, University of California, San Francisco, 1450 Third St., San Francisco, CA 94158, United States.
Melanie OttGladstone Institute of Virology, Gladstone Institutes, 1650 Owens Street, San Francisco, CA 94158.
James S FraserDepartment of Bioengineering and Therapeutic Sciences, University of California, San Francisco, 600 16 Street, San Francisco, CA 94158, United States.ORCID 0000-0002-5080-2859
Adam R RensloDepartment of Pharmaceutical Chemistry, University of California, San Francisco, 600 16 Street, San Francisco, CA 94158, United States.ORCID 0000-0002-1240-2846

Funding

Targeting Viroporins and Coronavirus M ProteinU19AI171110 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Nevan J Krogan · 2022 to 2026
$103.4M
A Synchrotron Radiation Structural Biology ResourcesP30GM133894 · NIGMS · STANFORD UNIVERSITY · PI Aina E. Cohen, KEITH O HODGSON · 2020 to 2026
$43.3M
User Training and OutreachP30GM124169 · NIGMS · UNIVERSITY OF CALIF-LAWRENC BERKELEY LAB · PI Gregory L Hura · 2017 to 2026
$28.6M
NIAID NIH HHS U19 AI171110NIGMS NIH HHS P30 GM124169NIGMS NIH HHS P30 GM133894
6 · The paper itself

Abstract

The COVID-19 pandemic made plain the need for effective antivirals acting on novel antiviral targets, among which viral macrodomains have attracted considerable attention. We recently described AVI-4206 (

Identifiers

PMID41279160
PMCPMC12632963

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.